IMMP trades 942.7% below Wall Street's consensus target of $4.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IMMP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Immutep Limited (IMMP) has a Wall Street consensus price target of $4.25, based on estimates from 3 covering analysts. With the stock currently trading at $0.41, this represents a potential upside of +942.7%. The company has a market capitalization of $60M.
Analyst price targets range from a low of $3.50 to a high of $5.00, representing a 35% spread in expectations. The median target of $4.25 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IMMP trades at a trailing P/E of -1.4x. Analysts expect EPS to grow +42.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NKTXNkarta, Inc. | $204M | $2.85 | $9.00 | +215.8% | Buy | — | 12 |
AGENAgenus Inc. | $131M | $3.15 | $7.33 | +132.7% | Buy | 4.0x | 11 |
IMVTImmunovant, Inc. | $7.9B | $38.51 | $45.00 | +16.9% | Buy | — | 23 |
RCUSArcus Biosciences, Inc. | $3.1B | $31.08 | $31.00 | -0.3% | Buy | — | 18 |
TPVGTriplePoint Venture Growth BDC Corp. | $196M | $4.83 | $8.95 | +85.3% | Hold | 5.2x | 12 |
FHTXFoghorn Therapeutics Inc. | $285M | $4.86 | $12.00 | +146.9% | Buy | — | 9 |
BMYBristol-Myers Squibb Company | $119.6B | $58.56 | $62.60 | +6.9% | Hold | 9.3x | 41 |
MRKMerck & Co., Inc. | $319.5B | $129.38 | $131.58 | +1.7% | Buy | 25.2x | 37 |
REGNRegeneron Pharmaceuticals, Inc. | $65.6B | $631.81 | $836.00 | +32.3% | Buy | 13.6x | 48 |
EXELExelixis, Inc. | $13.8B | $54.28 | $47.83 | -11.9% | Buy | 15.4x | 33 |
Quick answers to the most common questions about buying IMMP stock.
The consensus Wall Street price target for IMMP is $4.25, representing 942.7% upside from the current price of $0.4076. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IMMP has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $4.25 implies 942.7% upside from current levels.
IMMP's current price is $0.4076 with a consensus target of $4.25 (942.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for IMMP, while the most conservative target is $3.5. The consensus of $4.25 represents the median expectation. These targets typically reflect 12-month expectations.
IMMP is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IMMP stock forecast based on 3 Wall Street analysts shows a consensus price target of $4.25, with estimates ranging from $3.5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IMMP, with a "Buy" consensus rating and $4.25 price target (942.7% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IMMP analyst price targets range from $3.5 to $5, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.